Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815

Journal of Immunology

Volumn 162, Issue 6, 1999, Pages 3534-3540

  Bilsborough, Janine ^a   Van Pel, Aline ^a   Uyttenhove, Catherine ^a   Boon, Thierry ^a   Van Den Eynde, Benoît J ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDOREDUCTASE; TUMOR ANTIGEN;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA LIBRARY; GENE ACTIVATION; GENE TARGETING; IMMUNE RESPONSE; MASTOCYTOMA; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SPLEEN CELL; TUMOR CELL CULTURE; TUMOR REJECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CYTOTOXICITY, IMMUNOLOGIC; DNA, COMPLEMENTARY; EPITOPES, T-LYMPHOCYTE; IMMUNIZATION; INJECTIONS, INTRAPERITONEAL; MAST-CELL SARCOMA; MICE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OLIGOPEPTIDES; OXIDOREDUCTASES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033559510     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Maryanski, J., and T. Boon. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815: analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. Eur. J. Immunol. 12:406.
2. Uyttenhove, C., J. Maryanski, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040.
3. Brichard, V. G., G. Warnier, A. Van Pel, G. Morlighem, S. Lucas, and T. Boon. 1995. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur. J. Immunol. 25:664.
4. Van den Eynde, B., B. Lethé, A. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373.
5. Lethé, B., B. Van den Eynde, A. Van Pel, G. Corradin, and T. Boon. 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22:2283.
6. Levraud, J.-P., C. Pannetier, P. Langlade-Demoyen, V. Brichard, and P. Kourilsky. 1996. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the P815 murine tumor. J. Exp. Med. 183: 439.
7. d and is recognized by cytotoxic T lymphocytes against mouse tumor P815. Eur. J. Immunol. 24:2740.
8. Amar-Costesec, A., D. Godelaine, B. Van den Eynde, and H. Beaufay. 1994. Identification and characterization of the tumor-specific P1A gene product. Biol. Cell 81:195.
9. Uyttenhove, C., C. Godfraind, B. Lethé, A. Amar-Costesec, J.-C. Renauld, T. F. Gajewski, M.-T. Duffour, G. Warnier, T. Boon, and B. J. Van den Eynde. 1997. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int. J. Cancer 70:349.
10. Bianchi, R., U. Grohmann, M. L. Belladonna, S. Silla, F. Fallarino, E. Ayroldi, M. C. Fioretti, and P. Pucetti. 1996. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol. 157:1589.
11. Warnier, G., M.-T. Duffour, C. Uyttenhove, M. Perricaudet, C. Lurquin, H. Haddada, and T. Boon. 1996. Induction of a cytolytic T cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int. J. Cancer 67:303.
12. Fallarino, F., A. Ashikari, T. Boon, and T. F. Gajewski. 1997. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12-but not B7-1-transfected tumor cells. Int. Immunol. 9:1259.
13. Rosato, A., A. Zambon, G. Milan, V. Ciminale, D. D'Agostina, B. Macino, P. Zanovello, and D. Collavo. 1997. CTL response and protection against tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum. Gene Ther. 8:1451.
14. Atherton, E., C. J. Logan, and R. C. Sheppard. 1981. Peptide synthesis. Part 2. Procedures for solid phase synthesis using Nα-fluorenylmethysoxycarbamylamino-acid on polymide supports: synthesis of substance P and of acyl carrier protein 65-74 decapeptide. J. Chem. Soc. Perkin Trans. I 1:538.
15. Uyttenhove, C., J. Van Snick, and T. Boon. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815: rejection by syngeneic mice. J. Exp. Med. 152:1175.
16. Gajewski, T. F., J.-C. Renauld, A. Van Pel, and T. Boon. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor CTLs in vitro. J. Immunol. 154:5637.
17. Nair, A. P. K., I. D. Diamantis, J.-F. Conscience, V. Kindler, P. Hofer, and C. Moroni. 1989. A v-H-ras-dependent hemopoietic tumor model involving progression from a clonal stage of transformation competence to autocrine interleukin 3 production. Mol. Cell. Biol. 9:1183.
18. Mizushima, S., and S. Nagata. 1990. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18:5322.
19. Boon, T., J. Van Snick, A. Van Pel, C. Uyttenhove, and M. Marchand. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815: T lymphocyte-mediated cytolysis. J. Exp. Med. 152:1184.
20. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line. WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99.
21. Hansen, M. B., S. E. Nielsen, and K. Berg. 1989 Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119:203.
22. Davis, L. G., M. D. Dibner, and J. F. Battey. 1986. Guanidine isothiocyanate preparation of total RNA. In Basic Methods in Molecular Biology. Elsevier, New York, p. 130.
23. d gene. EMBO J. 2:245.
24. De Plaen, E., C. Lurquin, B. Lethé, P. van der Bruggen, V. Brichard, J.-C. Renauld, P. Coulie, A. Van Pel, and T. Boon. 1997. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 12:125.
25. Moskovitz, J., H. Weissbach, and N. Brot. 1996. Cloning and expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. Proc. Natl. Acad. Sci. USA 93:2095.
26. d MHC class I molecule. Semin. Immunol. 5:95.
27. Brändle, D., J. Bilsboraugh, T. Rülicke, C. Uyttenhove, T. Boon, and B. J. Van den Eynde. 1998. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28:4010.
28. Van den Eynde, B., and P. van der Bruggen. 1997. T cell-defined tumor antigens. Curr. Opin. Immunol. 9:684.
29. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
30. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921.
31. Boël, P., C. Wildmann, M.-L. Sensi, R. Brasseur, J.-C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE. a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167.
32. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.
33. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281.
34. Peifer, M. 1997. β-catenin as oncogene: the smoking gun. Science 275:1752.
35. Mandruzzato, S., F. Brasseur, G. Andry, T. Boon, and P. van der Bruggen. 1997. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186:785.
36. Brot, N., L. Weissbach, J. Werth, and H. Weissbach. 1981. Enzymatic reduction of protein-bound methionine sulfoxide. Proc. Natl. Acad. Sci. USA 78:2155.
37. Moskovitz, J., M. A. Rahman, J. Strassman, S. O. Yancey, S. R. Kushner, N. Brot, and H. Weissbach. 1995. Escherichia coli peptide methionine sulfoxide reductase gene: regulation of expression and role in protecting against oxidative damage. J. Bacteriol. 177:502.
38. Moskovitz, J., N. A. Jenkins, D. J. Gilbert, N. G. Copeland, F. Jursky, H. Weissbach, and N. Brot. 1996. Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Proc. Natl. Acad. Sci. USA 93:3205.
39. Srivastava, P. K. 1996. Do human cancers express shared protective antigens? or The necessity of remembrance of things past. Semin. Immunol. 8:295.
40. Mumberg, D., M. Wick, and H. Schreiber. 1996. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin. Immunol. 8:289.
41. Prehn, R. T., and J. M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769.
42. Ramarathinam, L., S. Sarma, M. Maric, M. Zhao, G. Yang, L. Chen, and Y. Liu. 1995. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol. 155:5323.
43. - transplantation antigen P198: a point mutation generates a new antigenic peptide. J. Exp. Med. 172:35.
44. Guéguen, M., J.-J. Patard, B. Gaugler, F. Brasseur, J.-C. Renauld, P. J. Van Cangh, T. Boon, and B. Van den Eynde. 1998. An antigen recognized by autologous CTL on a human bladder carcinoma. J. Immunol. 160:6188.